BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Bought by Jupiter Asset Management Ltd.

Jupiter Asset Management Ltd. boosted its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 137.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,471 shares of the biotechnology company’s stock after buying an additional 13,598 shares during the quarter. Jupiter Asset Management Ltd.’s holdings in BioMarin Pharmaceutical were worth $1,814,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in BMRN. Commonwealth Equity Services LLC raised its holdings in shares of BioMarin Pharmaceutical by 0.5% in the 2nd quarter. Commonwealth Equity Services LLC now owns 31,626 shares of the biotechnology company’s stock valued at $2,638,000 after purchasing an additional 156 shares in the last quarter. Bbva USA raised its holdings in shares of BioMarin Pharmaceutical by 20.5% in the 3rd quarter. Bbva USA now owns 934 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 159 shares in the last quarter. CIBC Private Wealth Group LLC raised its holdings in shares of BioMarin Pharmaceutical by 0.3% in the 2nd quarter. CIBC Private Wealth Group LLC now owns 62,270 shares of the biotechnology company’s stock valued at $5,196,000 after purchasing an additional 169 shares in the last quarter. Berman Capital Advisors LLC raised its holdings in shares of BioMarin Pharmaceutical by 45.2% in the 2nd quarter. Berman Capital Advisors LLC now owns 588 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 183 shares in the last quarter. Finally, Kistler Tiffany Companies LLC raised its holdings in shares of BioMarin Pharmaceutical by 17.1% in the 3rd quarter. Kistler Tiffany Companies LLC now owns 1,265 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 185 shares in the last quarter. Institutional investors own 94.15% of the company’s stock.

Shares of BioMarin Pharmaceutical stock opened at $90.22 on Friday. BioMarin Pharmaceutical Inc. has a 1 year low of $71.59 and a 1 year high of $92.17. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.03 and a current ratio of 4.49. The company has a market capitalization of $16.56 billion, a P/E ratio of 1,127.75, a PEG ratio of 2.90 and a beta of 0.49. The company’s fifty day moving average is $86.24 and its two-hundred day moving average is $81.34.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Tuesday, October 26th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.05. The business had revenue of $408.74 million for the quarter, compared to the consensus estimate of $435.29 million. BioMarin Pharmaceutical had a net margin of 0.86% and a return on equity of 2.02%. The business’s quarterly revenue was down 14.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.29 earnings per share. As a group, equities analysts expect that BioMarin Pharmaceutical Inc. will post 0.29 earnings per share for the current year.

In other news, EVP Jeffrey Robert Ajer sold 2,739 shares of BioMarin Pharmaceutical stock in a transaction dated Tuesday, October 26th. The shares were sold at an average price of $73.60, for a total value of $201,590.40. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Jean Jacques Bienaime sold 1,500 shares of the firm’s stock in a transaction dated Wednesday, December 1st. The shares were sold at an average price of $87.22, for a total transaction of $130,830.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,239 shares of company stock worth $1,267,980. Insiders own 1.69% of the company’s stock.

A number of equities research analysts have recently weighed in on BMRN shares. SVB Leerink restated a “buy” rating on shares of BioMarin Pharmaceutical in a report on Thursday, December 2nd. Wedbush reaffirmed an “outperform” rating and issued a $152.00 target price on shares of BioMarin Pharmaceutical in a research report on Thursday, October 28th. Piper Sandler increased their target price on shares of BioMarin Pharmaceutical from $119.00 to $121.00 and gave the company an “overweight” rating in a research report on Thursday, October 28th. Truist increased their target price on shares of BioMarin Pharmaceutical from $125.00 to $135.00 in a research report on Monday, January 10th. Finally, William Blair raised shares of BioMarin Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Monday, November 22nd. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $110.76.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical, Inc engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M.

Featured Article: What Is an EV Stock?

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.